Business
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Repositioned as a pure-play natural-based product company following strategic review and pipeline...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update\n\n\n\n\n Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization\n \n\n\n\n Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash\n \n\n\n\n Advancing Phase 2 clinical trial with Avenanthramide product\n \n\n\n\n Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer\n \n\n\n\n TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) --\n \n COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today reported its financial and operating results for the first quarter ended March 31, 2025 and provided a corporate update.\n \n\n\n\n Development Projects Update\n \n\n\n\n\n Pharmaceuticals:\n \n\n\n\n\n Avenanthramides Tablets in Clinical Development as an Anti-Inflammatory Product:\n \n\n\n During the first quarter of 2025, the Company announced successful Phase 1 results from the Phase 1 clinical study of its Avenanthramides tablets. That study involved 72 healthy subjects. There were no significant clinical adverse events observed from ascending doses ranging from 30 mg to 960 mg of the Company’s Avenanthramides tablets in that Phase 1 clinical study.\n \n\n As a result of the successful completion of that Phase 1 clinical study, the Company launched a Phase 2a clinical efficacy study of its Avenanthramides tablets on March 15, 2025. That study includes 20 patients divided in two cohorts. The first cohort of 10 patients who received a daily dose of 480 mg is completed. Subsequent to the end of the first quarter, data from those 10 patients was reviewed by independent members of the Data and Safety Monitoring Board (DSMB). The DSMB recommended that the study continue as planned with a second cohort of 10 patients who will receive a daily dose of 960 mg. The Company’s goal remains to complete the Phase 2a Clinical Efficacy Study during Q3, 2025.\n \n\n\n\n\n\n Nutraceuticals:\n \n\n\n\n\n The COSCIENS team is working to commercialize a new portfol...